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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a dis-
ease state characterized by an airflow limitation that is not
fully reversible and an insidiously progressive impairment
in health-related quality of life (HRQoL). Airflow limitation
is usually both progressive and associated with an abnormal
inflammatory response of the lungs to noxious particles or
gases. Inhaled bronchodilator therapy is the mainstay treat-
ment for COPD. When symptoms persist and are not ade-
quately controlled by short-acting bronchodilators, recent
guidelines recommend regular treatment with mono- or
combination therapies of long-acting bronchodilators (1, 2).
Previous clinical trials of long-acting anticholinergics (tio-
tropium) have uniformly demonstrated a beneficial effect in
terms of improving forced expiratory volume in one second
(FEV1) and reducing exacerbation rates compared with place-
bo or ipratropium (3-9). Tiotropium also improves HRQoL
compared with placebo or ipratropium (4, 5, 7, 10, 11). Recent
studies have also revealed that combination therapy with
tiotropium and long-acting  2-agonists (LABA) achieved a
greater improvement in FEV1 than the individual compo-
nent alone (12-14).
However, the role of inhaled corticosteroids (ICS) in the
management of COPD is less certain (15, 16). Although the
use of ICS remains one of the most controversial issues in
COPD pharmacotherapy, it is estimated that 41 to 50% of
patients with stable COPD receive ICS (17, 18). Moreover,
ICS was recommended by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD workshop) for sympto-
matic COPD patients with a FEV1 of <50% predicted (Stage
III: Severe COPD and Stage IV: Very Severe COPD) and re-
peated exacerbations (1). This treatment has been shown to
reduce the frequency of exacerbations and to improve health
status, whereas withdrawal from ICS treatment can lead to
exacerbations in some patients (19). Moreover, the combi-
nation of ICS and LABA is more effective than the individ-
ual components in stabilizing lung function or improving
HRQoL (20-24). However, the effects of long-acting anti-
cholinergics with and without ICS on lung function and
HRQoL has not been reported as yet. 
Previous animal studies suggested that corticosteroids may
enhance the effects of anticholinergics by influencing the dif-
ferential expression of M2 and M3 muscarinic receptors in
airway smooth muscles (25, 26). The present study was de-
signed to evaluate the efficacy of tiotropium/budesonide aga-
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The Combination of Tiotropium and Budesonide in the Treatment of
Chronic Obstructive Pulmonary Disease
Because additive effects of inhaled corticosteroids and long-acting anticholinergics
are unclear, we undertook this study to compare the efficacy of tiotropium alone and
tiotropium plus budesonide in patients with chronic obstructive pulmonary disease.
The study subjects were randomized to receive either tiotropium 18  g once daily
with or without budesonide 200  g twice daily for 6 weeks. The efficacy variables
were changes in trough forced expiratory volume in one second (FEV1), St. George’s
Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), and use of
rescue medication. One hundred patients were randomized and 81 completed the
study. The mean age was 64.0 yr, and the mean FEV1 was 39.7% predicted.
Compared with tiotropium alone (N=40), the tiotropium/budesonide combination
(N=41) was related to an improvement in the SGRQ total score (tiotropium -2.8
units and tiotropium/budesonide -5.6 units, p=0.003). 6MWD was improved by
13.5 m in the tiotropium group and by 22.5 m in the tiotropium/budesonide group
(p=0.031). Changes in trough FEV1 and the use of rescue medication were simi-
lar between two groups. In conclusion, compared with tiotropium alone, the tiotropi-
um/budesonide combination was related to an improved health-related quality of
life. These data support that low-dose budesonide may enhance the efficacy of
tiotropium. 
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inst tiotropium alone in patients with severe-to-very severe
COPD according to the GOLD criteria (1). The efficacy vari-
ables were trough FEV1, HRQoL, exercise capacity, and use
of rescue medication. 
MATERIALS AND METHODS
Study design and subjects
The study was a randomized, prospective, open-label design
and was performed at a single center (Kangnam General Hos-
pital, Yongin, Korea). The study was approved by the hos-
pital’s medical ethics committee, and written informed con-
sent was obtained from all patients before any study proce-
dure was undertaken.
Patients with a clinical diagnosis of COPD (according to
the GOLD guidelines) (1) and relatively stable airway obstruc-
tion with a postbronchodilator FEV1 of <50% predicted
and a ratio of FEV1 to forced vital capacity (FVC) of <70%
were prospectively enrolled. Patients had to be at least 40 yr
old, current or previous smokers (≥10 pack-years), and all
had experienced at least one episode of COPD exacerbation
within 2 yr before the first clinic visit.
Patients with any of the followings were excluded: a history
of asthma, allergic rhinitis, atopy, or an elevated blood eosi-
nophil count, a significant disease other than COPD, a severe
tuberculosis-sequelae (more than one lobe), or a recent his-
tory of myocardial infarction, heart failure, or cardiac arrhyth-
mia requiring medication. In addition, patients were excluded
if they were receiving oxygen therapy or had experienced any
respiratory infection or COPD exacerbation during the 6-
week period prior to screening. Patients with known hyper-
sensitivity to anticholinergic drugs, known symptomatic
prostatic hypertrophy, or narrow-angle glaucoma were also
excluded.
Study procedures
The study had a run-in period of one week and a treatment
period of 6 weeks, and involved four scheduled visits to clin-
ics, i.e., at the start of the run-in period (visit 1), at the start
of treatment (visit 2), and after 3 and 6 weeks of treatment
(visits 3 and 4). Following the screening visit (visit 1), eligi-
ble patients entered one-week run-in period to ensure clini-
cal stability (i.e., no exacerbations). At the start of the run-
in period, all inhaled short-acting anticholinergics, LABA,
and ICS were withdrawn. The patients continued to take
permitted COPD medications in stable doses, including
methylxanthines, mucolytics, oral steroids (at a dose of <10
mg per day prednisolone or equivalent), and short-acting
inhaled  2-agonists (salbutamol) for acute symptom relief.
Patients who successfully completed this phase entered the
6-week treatment period. At the end of the run-in period
(visit 2), eligible patients were randomly assigned using ran-
dom number table to treatment with tiotropium (SpirivaR,
Boehringer Ingelheim; Ingelheim am Rhein, Germany) 18
g once daily or treatment with tiotropium 18  g once daily
plus budesonide (PulmicortR, AstraZeneca, Korea) 200  g
twice daily. Tiotropium was supplied as a dry powder cap-
sule and was inhaled through a HandiHalerR device. Budes-
onide was inhaled from a TurbuhalerR, a dry powder inhaler
system. No other inhaled medications were permitted except
for salbutamol Metered Dose Inhalers (100 mg per actua-
tion) as needed for acute symptom relief.
Measurements
At the start of the run-in period, patients underwent a
medical examination, laboratory testing, and 12-lead echocar-
diography. During the treatment period, all patients com-
pleted a daily diary card and recorded their symptoms, the
inhalation of study medications, and the number of puffs of
rescue salbutamol administered.
Spirometry was conducted at the start of run-in period
(visit 1) and at the end of the run-in period (visit 2) and after
6-week treatment period (visit 4). Measurements were per-
formed using a spirometer (CPFS/D, MedGraphics; St. Paul,
MN, U.S.A.) that met the American Thoracic Society (ATS)
criteria (27). The highest FEV1 and FVC values obtained
from three technically adequate measurements were retained.
Baseline FEV1 was defined as FEV1 on the morning of the
randomization visit (visit 2) prior to the allocation of study
medication. Follow-up FEV1 was determined during visit
4 and was defined as the measurement taken after 6-week
treatment of the study medication. During visit 4, the morn-
ing dose of study medication was withheld and spirometry
was performed between 9AM to 10 AM to measure trough
levels because study medication was inhaled on the previous
day in the morning (approximately 9-10 AM for tiotropium
and budesonide) and in the evening (approximately 9-10 PM
for budesonide). Trough FEV1 difference was defined as the
change in trough FEV1 before (visit 2) and after (visit 4) 6-
week treatment. 
HRQoL was determined using the Korean version of the
St George’s Respiratory Questionnaire (SGRQ) and was
applied at the end of the run-in period (visit 2) and after 6-
week treatment (visit 4). The SGRQ is a disease-specific
instrument that contains 50 items in three subscales (symp-
toms, activity, and impacts) (28). Total SGRQ scores are
calculated from the responses obtained to all 50 items, and
a lower score represents an improvement. For SGRQ total
scores, a difference of ≥4 units was considered clinically
meaningful (29). Previous study validated that the Korean
version of SGRQ is well correlated with the dyspnea scale
in patients with COPD (30).
To determine exercise capacity, a 6-minute walk test (6M-
WT) was conducted according to the ATS guidelines (31), atTiotropium/Budesonide Combination Therapy in COPD 841
the end of the run-in period (visit 2) and after 6-week treatment
(visit 4). According to a previous study, the clinically meaning-
ful level of increase in 6-minute walk distance (6MWD) was
at least 54 m (32).
At each scheduled visit, details of clinical status and adverse
events, including exacerbations and withdrawals, were record-
ed. An exacerbation was defined as an increase in symptoms
requiring either a course of oral corticosteroids or antibiotics
or hospital admission. These changes in medication were
made at the investigator’s discretion. Patients were excluded
from the analyses if less than 80% of the scheduled study
medication had been taken. 
Statistical analysis
The present study was a preliminary study, and was the
first known comparison study of tiotropium once daily and
tiotropium once daily plus budesonide twice daily. In view
of the lack of previous research, no statistical hypotheses
were drawn and no formal sample size calculation was made.
The use of a preliminary study in clinical research is a well-
established scientific procedure because only through the
use of a preliminary study can statisticians clarify data dis-
tributions and determine appropriate sample sizes for full-
scale clinical trials.
Descriptive data for continuous variables are presented as
mean±standard error of the mean (SEM). T-tests were used
to compare changes between baseline and subsequent mea-
surements for each treatment group. Chi-squared or Fisher’s
exact test were used to compare categorical variables. All
patients with available on-treatment data were included in
the analyses. Statistical significance was considered at p<0.05,
and statistical analyses were performed using SPSS for Win-
dows Release 13.0 (SPSS; Chicago, IL, U.S.A.). 
RESULTS
The clinical characteristics of enrolled patients
Enrollment began in September 2005, and follow-up con-
cluded in March 2006. We assessed eligibility criteria in 148
potential study participants. Among these potential study
participants, 37 subjects did not meet eligibility criteria, and
11 subjects declined to participate in the study. We randomly
assigned the 100 patients who met all eligibility criteria: 50
to tiotropium and 50 to tiotropium plus budesonide. Of these
100 patients randomized, 81 completed the study and 19
were excluded from final analysis. The reasons for withdraw-
al were as follows: exacerbation of COPD (three patients in
the tiotropium group and two patients in the tiotropium/
budesonide group), pneumonia (one patient in the tiotropi-
um/bedesonide group), refusal of further involvement in the
study (three patients in the tiotropium group and one patient
in the tiotropium/budesonide group), poor medication com-
pliance (<80% of scheduled study medications; two patients
in the tiotropium group and two patients in the tiotropium/
budesonide group), and unavailability for follow-up (two
patients in the tiotropium group and three patients in the
tiotropium/budesonide group). 
Patients’ demographic and baseline characteristics are sum-
marized in Table 1. There were no significant differences in
demographic and baseline data, including smoking history,
lung function, SGRQ total score, and 6MWD. The mean
age of study subjects was 64.0±0.7 yr, with 91% being men.
Over 90% of study subjects previously received at least one
pulmonary medication. However, previous medication use
was not different between the two groups, and no one was
previously treated with tiotropium before the randomization.
Although a total of 25 patients had a past medical history
of tuberculosis (12 in the tiotropium group and 13 in the
tiotropium/budesonide group, p>0.05), sequelae were gen-
erally minimal (not more than one lobe).
Spirometry
The mean FEV1 of study subjects was 1.15±0.04 L (39.7
±0.9% predicted). The mean FEV1 on the morning of the
Data are presented as mean±SEM or No (%). 
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; SGRQ, St. George’s
Respiratory Questionnaire; 6MWD, 6-minute walk distance.
*, Fisher’s exact test.
Tiotropium
Tiotropium
+Budesonide
p
value
Subjects (No) 40 41
Age (yr) 63.8±0.8 64.2±0.7 >0.05
Sex (male)* 37 (92.5) 37 (90.2) >0.05
Duration of COPD (yr) 10.4±0.5 9.9±0.4 >0.05
Current/previous smoker (No) 18/22 17/24 >0.05
Smoking pack-years 33.6±1.8 35.4±1.6 >0.05
Previous history of tuberculosis 12 (30.0) 13 (31.7) >0.05
FEV1 (L) 1.17±0.04 1.13±0.04 >0.05
FEV1 (% predicted) 40.4±0.7 38.9±1.0 >0.05
FVC (L) 2.71±0.12 2.63±0.11 >0.05
FEV1/FVC (%) 45.9±1.3 44.3±1.4 >0.05
SGRQ total score 45.8±1.1 44.9±1.3 >0.05
6MWD (m) 221.8±4.5 227.7±3.7 >0.05
Pre-study medication, 
Any pulmonary medication* 38 (95.0) 37 (90.2) >0.05
Ipratropium bromide (inhaled) 25 (62.5) 27 (65.9) >0.05
Tiotropium (inhaled) 0 (0) 0 (0)
2-agonist (inhaled) 30 (75.0) 28 (68.3) >0.05
Steroid (inhaled) 16 (40.0) 18 (43.9) >0.05
Steroid (oral)* 2 (5.0) 1 (2.4) >0.05
Theophylline 13 (32.5) 11 (26.8) >0.05
Mucolytics 17 (42.5) 13 (31.7) >0.05
Table 1. Demographic data and baseline characteristics of study
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randomization visit (visit 2) was 1.17±0.04 L (40.4±0.7%
predicted) in the tiotropium group and 1.13±0.04 L (38.9
±1.0% predicted) in the tiotropium/budesonide group (p>
0.05) (Table 1). Trough FEV1 differences before (visit 2) and
after (visit 4) 6-week treatment were not different between
the tiotropium group (N=40, 46.4±10.4 mL) and the tio-
tropium/budesonide group (N=41, 61.0±14.5 mL) (p>
0.05) (Fig. 1). Next, subgroup analyses were performed in
order to investigate differences in treatment response. In the
tiotropium/budesonide combination group, age, smoking
status/history, baseline FEV1, and history of pulmonary tuber-
culosis did not affect trough FEV1 differences.
HRQoL
After 6-week treatment, mean improvements in SGRQ
total scores were -2.8±0.5 units in the tiotropium group
(N=40) and -5.6±0.7 units in the tiotropium/budesonide
group (N=41) (p=0.003) (Fig. 2), giving a mean difference of
-2.8 units. In addition, the proportions of patients who achi-
eved a clinically meaningful change (at least 4 units) in SGRQ
total score were 42.5% (17/40) in the tiotropium group and
73.2% (30/41) in the tiotropium/budesonide group (p=0.007),
giving a mean difference of 30.7%. Among three subscale
scores, symptoms scores were significantly improved in the
tiotropium/budesonide group (-10.0±2.3 units) compared
with the tiotropium group (-4.7±1.9 units) (p=0.002) (Fig.
2). However, activity and impacts scores were not different
between the two groups (p>0.05). In the subgroup analyses
of tiotropium/budesoinde combination, age, smoking status/
history, baseline FEV1, and history of pulmonary tuberculo-
sis were not different between improvement group (decrease
in SGRQ total score ≥4, N=30) and no improvement group
(decrease in SGRQ total score <4, N=11). 
6MWT
Of the 81 study subjects, 76 were able to perform the fol-
low-up 6MWT after 6-week treatment. Five subjects declined
to participate in the follow-up 6MWT (two in the tiotropi-
um group and three in the tiotropium/budesonide group).
6MWD was improved by 13.5±1.9 m in the tiotropium
group (N=38) and by 22.5±2.4 m in the tiotropium/budes-
onide group (N=38) (p=0.031). However, the proportions
of patients who achieved a clinically meaningful increase (at
least 54 m) in 6MWD were similar between the tiotropium
group (8/38, 21.1%) and the tiotropium/budesonide group
(11/38, 28.9%) (p>0.05) (Fig. 3). In the subgroup analyses
of tiotropium/budesoinde combination, age, smoking status/
history, baseline FEV1, and history of pulmonary tuberculo-
sis were not different between the improvement group (in-
crease in 6MWD ≥54 m, N=11) and the no improvement
group (increase in 6MWD <54 m, N=27). 
Rescue medication 
Patients recorded numbers of ‘‘as needed’’ puffs of salbuta-
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Fig. 1. Mean trough FEV1 differences before and after 6 weeks
of treatment in tiotropium (46.4±10.4 mL) and tiotropium/budes-
onide (61.0±14.5 mL) groups (p>0.05).  , change in; FEV1,
forced expiratory volume in one second.
Fig. 2. Mean differences in SGRQ total and subscale scores (sym-
ptoms, activity, and impact scores) before and after 6-week treat-
ment in tiotropium and tiotropium/budesonide groups.  , change
in; SGRQ, St George’s Respiratory Questionnaire.
*, p<0.05 for the group comparison.
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Fig. 3. Mean 6MWD differences before and after 6 weeks of treat-
ment in tiotropium (13.5±1.9 m) and tiotropium/budesonide gro-
ups (22.5±2.4 m).  , change in; 6MWD, 6-minute walk distance.
*, p<0.05 for the group comparison.
*
*mol. Total puffs during the 6-week treatment were not dif-
ferent between the two groups (the tiotropium group, N=
39, 59.8±3.2 puffs; the tiotropium/budesonide group, N=
41, 47.4±2.0 puffs) (p=0.089). 
Adverse events
The proportions of patients who experienced an incident
of mouth dryness were similar in the two groups (the tiotro-
pium group, 5.0%; the tiotropium/budesonide group, 4.8%).
However, more patients experienced hoarseness in the tio-
tropium/budesonide group (tiotropium/budesonide 4.8%;
tiotropium 0%).
DISCUSSION
In this 6-week study, the tiotropium/budesonide combi-
nation was found to improve SGRQ total and symptoms
scores compared with tiotropium alone. Moreover, combi-
nation treatment was found to be related to a higher propor-
tion of clinically meaningful improvement (at least 4 units)
in the SGRQ total score compared with tiotropium alone.
Although changes in trough FEV1 and the use of rescue
medication were not significant for the two groups, tiotropi-
um/budesonide increased mean 6MWD by 9 m versus tio-
tropium alone, and this was statistically significant (p=0.031).
However, this result does not meet the previously recom-
mended clinically meaningful level of increase in 6MWD
(31). In one study of 112 patients with stable COPD, the
smallest difference in 6MWD associated with a noticeable
clinical difference in the patient’s perception of exercise per-
formance was a mean of 54 m (32).
Although some studies showed that high-dose regimens
of ICS were more effective in slowing the decline of lung
function (33), the combination of formoterol with low or
medium doses of inhaled budesonide (320 or 640  g per
day) were also associated with improvement in lung function
and reduction in severe exacerbations compared to individu-
al component alone in other studies (22, 24). Therefore, we
chose a relatively low dose of inhaled budesonide (400  g
per day) rather than medium or high doses. However, the
low dose of ICS in this study may explain the lack of differ-
ences of trough FEV1 and modest improvement in 6MWD.
In present study we tried to compare the efficacy of tiotro-
pium/budesonide against tiotropium, but some study subjects
had a previous history of pulmonary medication including
short-acting inhaled anticholinergics (64.2%), ICS (42.0%)
and oral theophylline (29.6%) before screening visits. How-
ever, further data analyses revealed that changes in trough
FEV1, SGRQ total score, and 6MWD were not different
according to the previous medication of short-acting inhaled
anticholinergics, ICS, or theophylline. However, we cannot
completely exclude the possibility of the aggravation of HR-
QoL in the tiotropium group because of cessation of ICS (43.9
%). The COPE study revealed that the discontinuation of
fluticasone propionate in patients with COPD is associated
with a higher risk of exacerbation and of a significant deter-
ioration in aspects of HRQoL (19).
Contrary to previous studies (4-7, 9-11, 13, 14), the clin-
ical effects of tiotropium alone were not conspicuous in this
study. This discrepancy may be attributed to different study
periods and populations, i.e., FEV1 of <60-70% predicted
in the previous studies (4-7, 9-11, 13, 14) vs. FEV1 of <50%
predicted in the present study. In previous studies designed
to evaluate the efficacy of tiotropium, investigators allowed
continued ICS use, and therefore, in those studies, the con-
comitant use of ICS may have acted as a confounding vari-
able (ICS use, 42.1-88.7% of study subjects) (5-7, 9, 13, 14),
since corticosteroids may enhance the effects of anticholiner-
gics by influencing the differential expression of M2 and M3
muscarinic receptors (25, 26). Moreover, the concomitant
use of ICS and tiotropium was not definitively described in
some studies (4, 10, 11). Due to these limitations, previous
data about the efficacy of tiotropium may be biased by con-
comitant use of ICS, and the present study also supported
that ICS may enhance the efficacy of tiotropium. 
A total of 5 among 100 enrolled subjects (5%) experienced
acute exacerbation over the 6-week period, which correspond-
ed to previous studies (27.9% over 6 month and 42.5% over
1 yr) (8, 34). However, the short duration in the present study
was a limitation to evaluate the effect of budesonide combi-
nation on the frequencies of acute exacerbation.
In the present study, a total of 25 patients had a medical
history of tuberculosis (12 in the tiotropium group and 13 in
the tiotropium/budesonide group). Subgroup analyses revealed
no significant relationship according to the presence or ab-
sence of post-tuberculosis sequelae with respect to changes
in trough FEV1, 6MWD, and SGRQ total scores. 
Although the low compliance can be a real limitation of
inhaler therapy, the combination of tiotropium and budes-
onide did not increase the total frequencies of poor medica-
tion compliance, follow-up loss or refusal of further involve-
ment in the study compared with tiotropium alone (7% for
tiotropium/budesonide and 6% for tiotropium). 
However, the present study has several limitations; the
study was open-labeled rather than placebo-controlled and
was performed at a single center. Moreover, it was conducted
over a relatively short period. Due to these limitations, the
results of the present study cannot be generalized to the
whole COPD patient population. Nevertheless, this study
is the first to evaluate the effects of the tiotropium/budes-
onide combination in patients with severe to very severe
COPD. To confirm the additive effects of ICS and tiotropi-
um, further investigation is required with higher doses of
ICS for a long-term period.
In summary, the 6-week combination treatment of tiotropi-
um and budesonide was found to improve SGRQ total scores,
Tiotropium/Budesonide Combination Therapy in COPD 843symptoms scores, and 6MWD compared with tiotropium
alone. However, tiotropium/budesonide combination was
not related to the increase in trough FEV1 differences or
reduction of the salbutamol rescue medication.
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